特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
486815

1型糖尿病 (T1DM) の主要12カ国市場の予測:2017-2027年

Epiomic Epidemiology Series: Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027

出版日: | 発行: Black Swan Analysis | ページ情報: 英文 54 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
1型糖尿病 (T1DM) の主要12カ国市場の予測:2017-2027年
出版日: 2017年03月01日
発行: Black Swan Analysis
ページ情報: 英文 54 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の主要12カ国における1型糖尿病 (T1DM) の罹患状況を調査し、有病者数の推移と予測、国・併存症・重篤度別の内訳、主なマーカー抗体の陽性患者数の推移と予測、疾患の概要、危険因子、疾患の診断と予後、主な症状や併存症などをまとめています。

調査対象国

  • ブラジル
  • カナダ
  • 米国
  • フランス
  • ドイツ
  • インド
  • イタリア
  • 日本
  • ロシア
  • スペイン
  • 英国
  • 米国

目次

  • イントロダクション
  • 疾患の原因
  • リスク要因と予防法
  • 疾患の診断
  • 地域・民族による違い
  • 疾患の予後と臨床経過
  • 疾患に関連する主な共存症・特徴
  • 患者数の定量化の手法
  • 1型糖尿病の有病者数
  • 1型糖尿病の特徴
    • T1DM患者の共存症・後遺症
    • 網膜症を患うT1DM患者数
    • T1DM抗体の陽性患者数
  • 略語一覧
  • 他の出版物
  • 患者関連オンラインデータベース
  • 患者関連製品
  • オンライン価格データ・プラットフォーム
  • 参考文献
  • 付録
  • 図表
目次
Product Code: T1DM0010317

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Type 1 Diabetes Mellitus in 12 Major Markets

Type 1 Diabetes Mellitus (T1DM) is a multisystem disease that progressively destroys the pancreas' ability to produce insulin. This leads to a chronic condition of defective metabolism of fat, carbohydrates and proteins due to the lack of insulin. It occurs mainly in childhood and adolescents, however a rising number of latent autoimmune diabetes of adulthood (LADA) cases have been reported mainly due to a better understanding and diagnosis of the disease.

This report provides the current prevalent population for Type 1 Diabetes Mellitus across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Type 1 Diabetes Mellitus have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

There are many co-morbidities associated with Type 1 Diabetes Mellitus, including:

  • Chronic pancreatitis
  • Cystic fibrosis
  • Autoimmune disorders
  • Hyperglycaemia
  • Heart and blood vessel diseases (MI, Stroke, Atherosclerosis, Hypertension, Angina)
  • Neuropathy
  • Nephropathy (leading to CKD)
  • Ulcerations
  • Eye damage (retinopathy)
  • Foot damage
  • Ketoacidosis
  • Lower limb amputation
  • Skin/Mouth conditions
  • Pregnancy complications

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Type 1 Diabetes Mellitus market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Type 1 Diabetes Mellitus and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Type 1 Diabetes Mellitus prevalent population.
  • Identify sub-populations within Type 1 Diabetes Mellitus which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Type 1 Diabetes Mellitus patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Comorbid Conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line Prevalence for Type 1 Diabetes Mellitus
  • Features of Type 1 Diabetes Mellitus Patients
    • Comorbidities and Sequelae in T1DM Patients
    • T1DM patients with Retinopathy
    • Prevalence of T1DM defining antibodies
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Prevalence of Type 1 Diabetes Mellitus, total (000s)
  • Prevalence of Type 1 Diabetes Mellitus, males (000s)
  • Prevalence of Type 1 Diabetes Mellitus, females (000s)
  • T1DM patients by severity of Ketoacidosis, total (000s)
  • T1DM patients by kidney function, total (000s)
  • T1DM patients with Hypertension, total (000s)
  • Incidence of Lower Limb Amputations in T1DM patients, total (000s)
  • Incidence of Myocardial Infarction in T1DM patients, total (000s)
  • Incidence of Stroke in T1DM patients, total (000s)
  • Incidence of Angina in T1DM patients, total (000s)
  • T1DM patients with Peripheral Neuropathy, total (000s)
  • T1DM patients Diabetic Skin Conditions, total (000s)
  • T1DM patients Elevated HbA1c(>7.5%), total (000s)
  • T1DM patients with Coeliac Disease, total (000s)
  • T1DM patients with Retinopathy, total (000s)
  • T1DM patients with Retinopathy by Severity, total (000s)
  • T1DM patients with GADA antibodies, total (000s)
  • T1DM patients with ICA antibodies, total (000s)
  • T1DM patients with IA-2A antibodies, total (000s)
  • T1DM patients with IA-2BA antibodies, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • USA Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Canada Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Canada Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • France Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • France Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Germany Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Germany Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Italy Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Italy Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Spain Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Spain Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • UK Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • UK Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Japan Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Japan Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • India Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • India Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • China Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • China Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
  • Russia Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, males (000s)
  • Russia Prevalence of Type 1 Diabetes Mellitus by 5-yr age cohort, females (000s)
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.